1 - 3 of 3 articles
The role of epothilones in the treatment of locally advanced and metastatic breast cancer remains unclear. While the pivotal studies for ixabepilone were published between 2005 and 2010, and the agent received approval in 2007 from the U.S. Food and Drug Administration, its uptake in routine...
Chemotherapy still represents the mainstay of therapy for many breast cancer patients. Indeed, it is the only available option for the treatment of triple-negative disease. Moreover, targeted agents, in particular anti-HER2 compounds, show the highest efficacy when combined with chemotherapy....
The most successful tubulin-targeting agents in the treatment of breast cancer are the taxanes and the Vinca alkaloids. Vinorelbine, a vinca alkaloid derivative, has remarkable clinical activity in advanced breast cancer patients, and is currently used. Among the most critical limitations of...
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.